What Drugs Can Make Your Skin Darker?

Dozens of prescription and over-the-counter drugs can darken the skin, and drug-induced pigmentation accounts for roughly 10 to 20 percent of all cases of acquired hyperpigmentation.¹ The color shift is not always the brown or tan you might expect. Depending on the medication, skin can turn blue-gray, slate, greenish, or develop dark streaks in specific patterns. The list of culprits spans nearly every corner of the medicine cabinet, from antibiotics and heart drugs to chemotherapy agents and hormonal contraceptives, and the changes sometimes linger well after the drug is stopped.

How Common This Is and Who Gets Caught Off Guard

A recent systematic review pooling data across multiple studies found the overall incidence of drug-induced hyperpigmentation was about 37 percent among patients taking the implicated medications.² That number sounds alarming, but it is skewed by certain drug classes where darkening is almost expected. Tyrosine kinase inhibitors used in cancer treatment showed rates approaching 89 percent, and a newer class of weight-management drugs acting on melanocortin receptors came in around 71 percent. For commonly prescribed antibiotics the rate was closer to half, and antimalarials sat around 29 percent. The drugs most frequently named in case reports are minocycline, hydroxychloroquine, and hydroxyurea.²

Older adults tend to be disproportionately affected, partly because they take more medications for longer periods and partly because their skin is more susceptible to cumulative damage from both drugs and sunlight.¹ But younger patients are far from immune, especially those on long-term antibiotics for acne or immunosuppressive drugs for autoimmune conditions.

Antibiotics and Antimalarials

Minocycline, a tetracycline antibiotic widely prescribed for acne and rosacea, is one of the most recognizable offenders. Long-term use can deposit drug metabolites in the skin, producing a distinctive blue-gray discoloration that sometimes appears on the face, shins, or even inside the mouth.³ The color is not just melanin; the drug itself and iron-containing complexes get trapped in the skin’s deeper layers. People sometimes mistake the discoloration for bruising or a vascular problem, which delays the correct diagnosis.

Hydroxychloroquine, used heavily in lupus and rheumatoid arthritis, produces a similar bluish-green or brown staining, typically on the front of the legs and arms. In a case-control study, 92 percent of affected patients described the onset as bruises that simply never disappeared.⁴ The pigmentation was often preceded by ecchymotic areas, which are small zones of bleeding under the skin, suggesting the drug damages tiny blood vessels and then locks the resulting iron deposits into a visible stain. Palate involvement (darkening inside the mouth) was rarer but documented.

Heart Drugs and Psychiatric Medications

Amiodarone, a powerful anti-arrhythmia drug used for serious heart-rhythm disorders, can cause what clinicians informally call “blue man syndrome.” The slate-gray or bluish tint appears mainly on sun-exposed skin, the face and hands in particular. The discoloration results from a buildup of drug-pigment complexes in immune cells within the skin, combined with a photosensitivity reaction that amplifies the effect with UV exposure.⁵ Because amiodarone has an extraordinarily long half-life (it lingers in fat tissue for months), the color change can persist long after the drug is discontinued.

Chlorpromazine, one of the earliest antipsychotic medications and still used in some settings, is another long-known cause. Patients who have taken it for years can develop blue-gray pigmentation in sun-exposed areas, sometimes alongside changes in the cornea and lens of the eye.⁶ The combined skin-and-eye involvement makes this side effect clinically distinctive and, for the patient, particularly distressing. Newer antipsychotics have largely replaced chlorpromazine in routine practice, which has made this pattern less common, but it still turns up in patients on older regimens.

Chemotherapy and Cancer-Targeted Drugs

Several chemotherapy agents darken the skin, though the patterns vary dramatically. Bleomycin, used for certain lymphomas and testicular cancers, is famous for producing “flagellate hyperpigmentation,” streaky, whip-like dark lines that typically appear on the trunk and back. The pattern is so distinctive that experienced oncologists recognize it on sight. Histologically, the drug triggers overactive melanocytes and disrupts the normal turnover of skin cells, causing melanin to pile up in the upper layers of the skin.⁷ These marks are painless and non-itchy, which can be reassuring, but they often catch patients off guard after just a few treatment cycles.⁸

Tyrosine kinase inhibitors, a newer generation of targeted cancer therapies, have a complicated relationship with skin color. Imatinib, perhaps the best known of this class, usually causes lightening of the skin because it interferes with melanocyte activity. But paradoxically, it can also cause darkening, and some patients develop both lighter and darker patches simultaneously.⁹ When darkening occurs, it often resembles melasma-like patches on the face or shows up as blue-gray changes in the mouth, teeth, and nails.¹⁰ The unpredictability is notable: two patients on the same dose can have opposite skin-color responses.

Hormonal Medications and Melasma

Hormonal therapies, especially oral contraceptives and hormone replacement therapy, are major risk factors for melasma, the splotchy brown-to-gray facial darkening that disproportionately affects women. A pharmacovigilance analysis of the FDA’s adverse event database confirmed that hormone therapies are among the strongest drug-related triggers for melasma.¹¹ Estrogen stimulates melanocyte growth and prompts surrounding skin cells to release pigment-boosting signals, while progesterone increases both the number of melanocytes and the activity of the enzyme that produces melanin.¹¹

This mechanism explains why melasma also spikes during pregnancy, when the body produces its own surge of estrogen and progesterone. The pregnancy-related version often improves after delivery, but drug-induced melasma can be stubbornly persistent. Women who developed melasma on birth control pills sometimes find the patches linger for months or years after switching to a non-hormonal method, especially if they have darker skin tones to begin with.

Melanocortin Receptor Drugs

A newer category worth understanding is drugs that activate melanocortin receptors, the same receptors your body uses to ramp up melanin production during UV exposure. Afamelanotide, a subcutaneous implant approved for a rare condition called erythropoietic protoporphyria (where sunlight causes severe pain), deliberately increases melanin density as part of its therapeutic effect. In a placebo-controlled study of 65 participants, everyone receiving three months of treatment showed a significant rise in melanin.¹²

Setmelanotide, approved for certain rare genetic obesity conditions, also acts partly through this pathway. About 56 percent of patients reported noticeable tanning during the first month of treatment.¹² Unlike most of the other drugs on this list, the darkening here is functionally identical to a natural tan, driven by increased eumelanin production rather than drug-pigment deposits. The skin-color change is sometimes listed as an expected side effect rather than an adverse event.

Unregulated Tanning Peptides

Melanotan II occupies a strange legal gray zone. It is an unlicensed synthetic peptide that mimics the body’s melanocortin hormones, and it has become popular through social media as a way to tan without UV exposure.¹³ Users typically inject it subcutaneously, sometimes using nasal sprays. The tanning effect is real: the peptide activates melanocortin-1 receptors on melanocytes and stimulates eumelanin production. But “real” does not mean “safe.” The product is unregulated, the purity and dosing of what people buy online are unknown, and case reports describe serious complications including sympathomimetic overdrive (a dangerous surge in heart rate and blood pressure), rhabdomyolysis (breakdown of muscle tissue), kidney dysfunction, and priapism.¹⁴¹⁵

There is essentially no clinical data supporting the doses recommended by the websites selling Melanotan II, and the side-effect profile is poorly characterized. The fact that it produces visible tanning gives users a false sense that it is working as intended, when in reality they have no way of knowing what else the injected substance is doing.

Eye Drops That Darken the Surrounding Skin

Prostaglandin analogue eye drops, prescribed for glaucoma, can darken the skin around the eyes. Bimatoprost is the best-studied example. The periocular hyperpigmentation tends to appear gradually and, reassuringly, has been reported as completely reversible when the drops are stopped.¹⁶ The time of onset varies from patient to patient, and it is most noticeable in lighter-skinned individuals. The same prostaglandin pathway also darkens the iris itself over time, a change that is not reversible, which sometimes surprises patients who were only warned about the skin effect.

Silver and Heavy Metals

Technically these are not “drugs” in the prescription sense, but silver-containing products and certain heavy metals are consumed with the intention of treating health conditions, and they deserve a mention because the resulting color changes are dramatic and essentially permanent. Argyria, the medical term for silver-induced discoloration, produces a diffuse slate-gray or bluish tinge that typically affects the face and hands first.¹⁷ Colloidal silver, marketed as an alternative remedy for infections and immune support, is the most common source today. The silver particles deposit in the skin and, once embedded, are extraordinarily difficult to remove.¹⁸

Chronic arsenic exposure, whether from contaminated water, certain traditional medicines, or occupational contact, causes a different pattern: “raindrop pigmentation,” where the skin develops a speckled appearance of dark and light spots, often with thick, painful keratotic lesions on the palms and soles.¹⁹ This pattern is considered precancerous and warrants urgent medical investigation.

Why Sunlight Makes Everything Worse

A recurring theme across nearly every class of pigment-inducing drug is that sunlight amplifies the effect. Many of these medications are photosensitizers: they absorb UV light and trigger chemical reactions in the skin that boost melanin production, cause inflammation, or both. The photoexcitation of drug molecules in the skin can set off oxidative stress and downstream changes in pigment synthesis that go well beyond what either the drug alone or sunlight alone would produce.²⁰ This is why drug-induced pigmentation so often favors the face, forearms, and hands, areas with the most UV exposure.

For patients on any of the drugs discussed here, consistent sun protection is one of the few genuinely useful preventive measures. Broad-spectrum sunscreen, hats, and UV-protective clothing will not eliminate the risk, but they reduce the compounding effect of light on the drug’s pigment-inducing potential. People are frequently told to “avoid the sun” in the package insert but rarely told why, and understanding the photosensitivity mechanism makes the advice feel less arbitrary and more worth following.

Fixed Drug Eruptions and Post-Inflammatory Darkening

Some drugs darken the skin indirectly by triggering an inflammatory reaction that leaves pigment behind. Fixed drug eruptions are a well-known example: the same spot on the skin flares up each time the offending drug is taken, then resolves into a dark, persistent stain. Biopsies of these lesions show a characteristic inflammatory pattern with immune cells carrying melanin fragments deep into the skin.²¹ The result is post-inflammatory hyperpigmentation that can persist for months or even years, and this effect is more visible and more prolonged in people with darker skin tones.²¹

Common culprits for fixed drug eruptions include certain antibiotics (trimethoprim-sulfamethoxazole is a classic offender), nonsteroidal anti-inflammatory drugs, and some anticonvulsants. The tricky part is that the initial eruption can be mild, just a single red or dusky patch, and the patient may not connect it to the drug. By the time the persistent dark spot develops, the inflammatory phase is over and the connection is harder to make.

Does the Darkening Go Away?

Reversibility varies enormously by mechanism. When the darkening is driven by increased melanin production (as with hormonal medications or melanocortin-receptor drugs), stopping the drug often allows the pigmentation to fade over weeks to months, though in some cases it never returns fully to baseline. The bimatoprost-related periocular darkening, as noted, appears to be completely reversible.¹⁶

When the darkening involves actual deposition of drug-pigment complexes or metals in the skin, the picture is much less optimistic. Minocycline pigmentation can take months to years to fade after the antibiotic is stopped, and amiodarone’s blue-gray hue persists because the drug’s metabolites remain trapped in tissue long after the last dose. Argyria from silver is considered irreversible by conventional treatments, though some case reports describe partial improvement with laser therapy. The general rule is that the deeper the pigment sits in the skin (dermis versus epidermis), the longer it takes to clear, and dermal deposits are the ones most likely to be permanent.

Skin Tone and Unequal Visibility

Drug-induced pigmentation does not affect all skin types equally. In people with lighter skin, color changes are often noticed quickly because the contrast is stark. In people with darker baseline skin tones, the same pigmentary changes may go unrecognized for longer, but when post-inflammatory hyperpigmentation occurs, it tends to be more intense and more persistent. This creates a clinical paradox: the populations in whom drug-induced darkening is hardest to spot are often the populations in whom the cosmetic and psychological burden of that darkening, once it does become apparent, is greatest.

Most of the foundational research on drug-induced pigmentation was conducted in lighter-skinned populations, and dermatologic textbooks have historically illustrated these conditions with images from fair-skinned patients. This has improved in recent years, but it means some clinicians are less practiced at recognizing drug-induced pigmentation in darker skin. If you have a darker complexion and notice any new discoloration while taking a long-term medication, raising it with your doctor rather than waiting is sensible, because early identification and drug substitution are the most effective interventions.

Medications That Darken Nails and Mucous Membranes

Skin is not the only target. Many of the same drugs that darken exposed skin also affect nails and the lining of the mouth. Hydroxyurea, used for sickle cell disease and certain cancers, is notorious for turning nails brown or black, especially in patients with darker skin. Imatinib can darken the oral mucosa, teeth, and nails without affecting the surrounding skin at all.¹⁰ Melanotan II injections have been linked to mucosal pigmentation changes inside the mouth.¹³ These changes sometimes alarm patients or their dentists, who may suspect melanoma or another worrisome condition before the medication history comes to light.

When nail or mucosal darkening appears alongside new skin pigmentation, the drug connection becomes easier to make. But when it appears in isolation, it can trigger unnecessary biopsies and anxiety. Keeping a medication list updated and sharing it with every provider, including your dentist, reduces the chance of a diagnostic goose chase.

1
PubMed. Drug-induced skin pigmentation: Epidemiology, diagnosis and treatment
2
PubMed Central. Drug induced hyperpigmentation: systematic review and meta-analysis
3
PubMed Central. Minocycline-Induced Blue-Gray Discoloration
4
JAMA Dermatology. Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus: A Case-Control Study
5
PubMed Central. Blue man syndrome
6
PubMed. Chlorpromazine-induced skin pigmentation with corneal and lens opacities
7
JAMA Dermatology. Flagellate Hyperpigmentation Following Intralesional Bleomycin Treatment of Verruca Plantaris
8
PubMed Central. Bleomycin-induced flagellate-like skin pigmentation in a 15-year-old girl: a case report and review
9
PubMed. Imatinib induced melasma-like pigmentation: Report of five cases and review of literature
10
JAAD Case Reports. Blue-gray hyperpigmentation associated with imatinib therapy: A case report and review of the literature
11
PubMed Central. Melasma secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)
12
PubMed Central. An overview of benefits and risks of chronic melanocortin‐1 receptor activation
13
PubMed Central. Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report
14
PubMed. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis
15
PubMed Central. Melanotan Tanning Injection: A Rare Cause of Priapism
16
PubMed. Clinical course of bimatoprost-induced periocular skin changes in Caucasians
17
PubMed Central. A case of argyria following colloidal silver ingestion
18
PubMed Central. Clinical and Forensic Aspects of the Different Subtypes of Argyria
19
PubMed. Palmoplantar keratoderma with mottled pigmentation: A clue to chronic arsenicosis
20
PubMed Central. Drug-Induced Photosensitivity-From Light and Chemistry to Biological Reactions and Clinical Symptoms
21
PubMed Central. Generalized fixed drug eruptions in skin of color